All In Biotech

Drug Trial Radar · NCT07216443

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Dec 9, 2025

Primary completion

Nov 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Orca Biosystems, Inc.Industry
Sponsor type
Industry
First posted
Oct 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) from an 8/8 human leukocyte antigen (HLA)-matched (reduced-intensity conditioning \[RIC\] or nonmyeloablative \[NMA\] cohorts) or 7/8 HLA-mismatched (RIC cohort) donor for hematologic malignancies. Orca-T is an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons).

Conditions

  • Leukemia, Myeloid, Acute
  • Myelodysplastic Syndromes
  • Mixed Phenotype Acute Leukemia

Interventions

  • Orca-TBiological

    An allogeneic stem cell and T-cell immunotherapy biologic

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 8/8 HLA-Matched RIC Cohort: GVHD-free and relapse-free survival (GRFS)Time frame: Day 0 through day +365 after transplantation
  2. 8/8 HLA-Matched NMA Cohort: Incidence of neutrophil engraftmentTime frame: Day 0 through day +28 after transplantation
  3. 8/8 HLA-Matched NMA Cohort: Time to neutrophil engraftmentTime frame: Day 0 through day +28 after transplantation
  4. 7/8 HLA-Mismatched RIC Cohort: Incidence of neutrophil engraftmentTime frame: Day 0 through day +28 after transplantation
  5. 7/8 HLA-Mismatched RIC Cohort: Time to neutrophil engraftmentTime frame: Day 0 through day +28 after transplantation

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • UCLA Department of Medicine

    Los Angeles, California · Recruiting

  • Colorado Blood Cancer Institute / St. Luke's Medical Center

    Denver, Colorado · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Weill Cornell Medicine - New York Presbyterian Hospital

    New York, New York · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Vanderbilt University, Ingram Cancer Center

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.